Effect of KW-6356, a novel adenosine A2A receptor antagonist/inverse agonist, on motor and non-motor symptoms in Parkinson’s disease patients as an adjunct to levodopa therapy: Results of Phase 2b study
Objective: To evaluate the efficacy and safety of KW-6356 in Parkinson’s disease (PD) patients with levodopa therapy, irrespective of the presence of wearing-off (WO). Background:…Improving the patient self-awareness of the first motor fluctuations in early Parkinson’s disease with a wearable sensor
Objective: We aim to assess if the use of a wearable sensor can increase the patient and caregiver self-awareness of the first motor fluctuations (MF).…Safinamide as an adjunct to Levodopa Therapy in Asian and Caucasian Patients with Parkinson’s Disease and Motor Fluctuations: A post-hoc Analysis of the SETTLE study
Objective: This study evaluated the efficacy and safety outcomes of safinamide as a levodopa adjunct therapy in Asian and Caucasian patients with Parkinson’s disease. Background:…SAFINAMIDE: REAL LIFE STUDY. EFFICACY IN SWITCH FROM RASAGILINA AND LOW-DOSE TREATMENT.
Objective: Evaluate the efficacy of safinamide in fluctuations in Parkinson's disease in real life. Analysis by subgroups: Switch rasagiline to safinamide and treatment with low…Clinical Outcomes and Disease Burden of Advanced Parkinson’s Disease Patients Treated with Oral Medication Vs. Device-Aided Therapies: Preliminary Results from the University of Florida Registry Analysis
Objective: Compare real-world clinical outcomes of Parkinson’s disease (PD) patients with moderate/severe motor fluctuations and/or dyskinesia treated with oral medications compared to device-aided therapies. Background:…Exploring the morning akinesia in Parkinson’s disease with the wearable sensor STAT-ON
Objective: To detect the morning akinesia (MA) through the analysis of the gait fluidity (GF) measured by the sensor STAT-ON. Background: The STAT-ON sensor's detection…Duration of continuous “Good On” intervals and number of motor fluctuations after treatment with IPX203 vs immediate-release carbidopa-levodopa in Parkinson’s disease patients with motor fluctuations.
Objective: To compare the duration of continuous “On” without troublesome dyskinesia (“Good On”) intervals and number of motor fluctuations per day in Parkinson’s disease (PD)…Gait analysis using Wearable Sensors: different gait metrics can differentiate Parkinson’s Disease Patients from Healthy Controls and Parkinson’s Disease patients in different medication status
Objective: To identify which gait metrics better distinguish PD-OFF from PD Best-ON and PD from HC, using a dimensionality-reduction method Background: Objective gait analysis using…Analysis of Amantadine formulations for OFF and Dyskinesia in Parkinson Disease
Objective: Evaluate the effects of amantadine formulations on the treatment of OFF and dyskinesia in Parkinson’s patients. Background: There are currently three formulations of amantadine…Influence of Dopamine Transporter Gene Polymorphism on Wearing Off
Objective: To study the influence of Dopamine transporter gene polymorphism on Wearing off (WO) through 19 items wearing off questionnaire (WOQ-19) Background: The dopamine transporter…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 23
- Next Page »